Premium
IMP‐6 Carbapenemase‐Producing Enterobacteriaceae Bacteremia Successfully Treated with Amikacin‐Meropenem in Two Patients
Author(s) -
Nakakura Ichiro,
Ogawa Yoshihiko,
Sakakura Kota,
Imanishi Kaori,
Hirota Kazuyuki,
Shimatani Yasuaki,
Uehira Tomoko,
Nakamori Shoji,
Sako Rumi,
Doi Toshiyuki,
Yamazaki Kunio
Publication year - 2017
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1984
Subject(s) - amikacin , meropenem , medicine , bacteremia , cefepime , antibiotics , adverse effect , enterobacteriaceae , dose , surgery , intensive care medicine , microbiology and biotechnology , imipenem , biology , antibiotic resistance , escherichia coli , biochemistry , gene
Infections caused by carbapenemase‐producing Enterobacteriaceae (CPE) are becoming increasingly common worldwide. Although CPE infections can be fatal, few reports in the literature have described effective and successful treatments for infectious diseases caused by several types of IMP CPE, and, to our knowledge, no reports have described the successful treatment of IMP‐6 CPE infections. We describe two patients who developed bacteremia caused by IMP‐6 CPE after surgery for cancer who were successfully treated with amikacin plus high‐dose prolonged‐infusion meropenem. Both patients were treated over a 2‐week period using amikacin 15 mg/kg at various intervals based on therapeutic drug monitoring and meropenem 2000 mg infused over 3 hours every 12 hours. The dosages of amikacin and meropenem were determined based on the creatinine clearance of each patient. Both patients were cured of their bacteremia and did not experience any antibiotic‐related adverse effects. Based on the outcomes of these patients, it appears that amikacin plus high‐dose prolonged‐infusion meropenem may be safe and effective for the treatment of bacteremia caused by IMP‐6 CPE.